<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04752930</url>
  </required_header>
  <id_info>
    <org_study_id>SixthSunYetSen-ctDNA</org_study_id>
    <nct_id>NCT04752930</nct_id>
  </id_info>
  <brief_title>ctDNA as a Assisted Diagnosis, Early Intervention and Prognostic Marker for Peritoneal Metastases From Colorectal Cancer</brief_title>
  <official_title>Circulating Tumor DNA (ctDNA) as a Assisted Diagnosis, Early Intervention and Prognostic Marker for Peritoneal Metastases From Colorectal Cancer: A Prospective, Open-label, Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, randomized controlled clinical trial, by monitoring the&#xD;
      serum ctDNA mutational profile using NGS, aiming to elucidate the correlation between the&#xD;
      postoperative ctDNA status and the assisted diagnosis, early intervention and prognosis for&#xD;
      colorectal cancer peritoneal metastases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 24, 2020</start_date>
  <completion_date type="Anticipated">August 24, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 24, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peritoneal Metastasis Free Survival (PMFS)</measure>
    <time_frame>Through study completion, up to 3 years</time_frame>
    <description>The survival rate without peritoneal metastasis (oligometastatic) at 24 months after radical resection of colorectal cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection Rate (DR)</measure>
    <time_frame>Interim analyses: After 69 patients have been enrolled, up to 1.5 years</time_frame>
    <description>DR of ctDNA monitoring for predicting peritoneal metastasis with abdominal exploration as the reference.&#xD;
DR of imageological examination for predicting peritoneal metastasis with abdominal exploration as the reference.&#xD;
DR of combination of ctDNA monitoring and imageological examination for predicting peritoneal metastasis with abdominal exploration as the reference.&#xD;
Will be compared in both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Percent Agreement (PPA)</measure>
    <time_frame>Interim analyses: After 69 patients have been enrolled, up to 1.5 years</time_frame>
    <description>PPA of ctDNA monitoring for predicting peritoneal metastasis with abdominal exploration as the reference.&#xD;
PPA of imageological examination for predicting peritoneal metastasis with abdominal exploration as the reference.&#xD;
PPA of combination of ctDNA monitoring and imageological examination for predicting peritoneal metastasis with abdominal exploration as the reference.&#xD;
Will be compared in both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative Percent Agreement (NPA)</measure>
    <time_frame>Interim analyses: After 69 patients have been enrolled, up to 1.5 years</time_frame>
    <description>NPA of ctDNA monitoring for predicting peritoneal metastasis with abdominal exploration as the reference.&#xD;
NPA of imageological examination for predicting peritoneal metastasis with abdominal exploration as the reference.&#xD;
NPA of combination of ctDNA monitoring and imageological examination for predicting peritoneal metastasis with abdominal exploration as the reference.&#xD;
Will be compared in both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time of peritoneal metastasis diagnosed after radical surgery</measure>
    <time_frame>Interim analyses: After 69 patients have been enrolled, up to 1.5 years</time_frame>
    <description>Will be compared in both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peritoneal Cancer Index (PCI) Score</measure>
    <time_frame>Interim analyses: After 69 patients have been enrolled, up to 1.5 years</time_frame>
    <description>This scale measures the extent of peritoneal cancer throughout the peritoneal cavity.&#xD;
The range of this scale is from 0 to 39.&#xD;
0 = no disease within the peritoneal cavity&#xD;
0-9 = minimal disease&#xD;
10-29 = moderate disease&#xD;
30-39 = extensive disease&#xD;
Lower values are considered a better outcome for the patient.&#xD;
Will be compared in both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completeness of Cytoreduction (CC) Score</measure>
    <time_frame>Interim analyses: After 69 patients have been enrolled, up to 1.5 years</time_frame>
    <description>The degree to which the disease was able to be excised during the procedure.&#xD;
This scale ranges from CC0-CC3.&#xD;
CC0 = all disease has been cleared, with no visible peritoneal carcinomatosis after CRS&#xD;
CC1 = microscopic disease remains (Nodules persisting &lt; 2.5 mm after CRS)&#xD;
CC2 = macroscopic disease remains (Nodules persisting between 2.5 mm and 2.5 cm)&#xD;
CC3 = Substantial Macroscopic disease remains (Nodules persisting &gt; 2.5 cm)&#xD;
Lower values are considered a better outcome, with CC0/1 classed as favourable and CC2/3 indicating an incomplete clearance of disease.&#xD;
Will be compared in both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ctDNA clearance rate before and after CRS+HIPEC treatment</measure>
    <time_frame>Interim analyses: After 69 patients have been enrolled, up to 1.5 years</time_frame>
    <description>Will be compared in both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of Disease Free Survival (DFS) at 3 years after radical resection of colorectal cancer</measure>
    <time_frame>Through study completion, up to 3 years</time_frame>
    <description>Whether the patient is still alive and free of disease or not.&#xD;
Will be compared in both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Overall Survival (OS) at 3 years after radical resection of colorectal cancer</measure>
    <time_frame>Through study completion, up to 3 years</time_frame>
    <description>Whether the patient is still alive or not.&#xD;
Will be compared in both arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Peritoneal Metastases</condition>
  <arm_group>
    <arm_group_label>ctDNA monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ctDNA monitoring will be performed at protocol-specified intervals and requirement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imageology (SOC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imaging examination will be performed at protocol-specified intervals and requirement</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ctDNA monitoring</intervention_name>
    <description>Patients who undergoing radical surgery for colorectal cancer for 6~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled, and diagnostic laparoscopy will be performed immediately after enrollment. Patients with positive peritoneal metastasis (PCI score &lt;20) will be treated with CRS+HIPEC. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months in patients with negative peritoneal metastasis. Laparoscopy will be performed when imaging suggested peritoneal metastasis (oligometastases). Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.</description>
    <arm_group_label>ctDNA monitoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Imageology</intervention_name>
    <description>Patients who undergoing radical surgery for colorectal cancer for 6~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled. and there will be no need to conduct endoscopic exploration immediately after enrollment. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months until imaging suggested peritoneal metastasis (oligometastases). Patients with positive peritoneal metastasis (PCI score &lt;20) will be treated with CRS+HIPEC. Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.</description>
    <arm_group_label>Imageology (SOC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be a man or woman of at 18-75;&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of&#xD;
             0-21；&#xD;
&#xD;
          -  Patients with primary colorectal cancer proven by pathology；&#xD;
&#xD;
          -  Patients with high risk factors for peritoneal metastasis (simultaneous peritoneal&#xD;
             metastasis, ovarian metastasis, PT4, CT4, tumor perforation, tumor-complete intestinal&#xD;
             obstruction, mucinous adenocarcinoma/signet ring cell carcinoma of PT3, positive&#xD;
             surgical margin, and tumor rupture and hemorrhage);&#xD;
&#xD;
          -  6-12 months after colorectal cancer radical surgery, patients who have two consecutive&#xD;
             positive ctDNA tests within one month;&#xD;
&#xD;
          -  Patients who have finished standard adjuvant therapy after surgery; (Choose 5-FU or&#xD;
             5-FU analog-based chemotherapy regimen, and the perioperative chemotherapy should not&#xD;
             exceed 6 months)；&#xD;
&#xD;
          -  Patients who are negative of recurrence or metastasis in conventional oncology&#xD;
             examination (serology, endoscopy, imaging) ;&#xD;
&#xD;
          -  Written informed consent must be obtained from patients and ability for patients to&#xD;
             comply with the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who were diagnosed with other malignant tumors within 2 years before&#xD;
             diagnosis of colorectal cancer;&#xD;
&#xD;
          -  ASA class Ⅳ to Ⅴ;&#xD;
&#xD;
          -  Patients who have other existence of distant metastasis outside the abdomen;&#xD;
&#xD;
          -  Patients with serious mental illness;&#xD;
&#xD;
          -  Patients with severe cardiovascular disease, uncontrollable infections, or other&#xD;
             uncontrollable co-diseases;&#xD;
&#xD;
          -  Patients who cannot be followed up as scheduled;&#xD;
&#xD;
          -  Patients who participated in other clinical studies within 3 months prior to the&#xD;
             trial;&#xD;
&#xD;
          -  Pregnant or nursing women, men or women of childbearing potential who are unwilling to&#xD;
             employ adequate contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hui Wang, MD, PhD</last_name>
    <phone>13926424886</phone>
    <email>wang89@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tenghui Ma, MD, PhD</last_name>
    <phone>13560232462</phone>
    <email>austin_2004@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sixth Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012 Jan 20;30(3):263-7. doi: 10.1200/JCO.2011.37.1039. Epub 2011 Dec 12.</citation>
    <PMID>22162570</PMID>
  </reference>
  <reference>
    <citation>Yonemura Y, Bandou E, Kawamura T, Endou Y, Sasaki T. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur J Surg Oncol. 2006 Aug;32(6):602-6. Epub 2006 Apr 17. Review.</citation>
    <PMID>16617004</PMID>
  </reference>
  <reference>
    <citation>Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron G, Guilloit JM, Meeus P, Goéré D, Bonastre J. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009 Feb 10;27(5):681-5. doi: 10.1200/JCO.2008.19.7160. Epub 2008 Dec 22.</citation>
    <PMID>19103728</PMID>
  </reference>
  <reference>
    <citation>Baratti D, Kusamura S, Deraco M. The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus. J Surg Oncol. 2008 Sep 15;98(4):258-62. doi: 10.1002/jso.21056.</citation>
    <PMID>18726888</PMID>
  </reference>
  <reference>
    <citation>Esquivel J, Chua TC, Stojadinovic A, Melero JT, Levine EA, Gutman M, Howard R, Piso P, Nissan A, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Shen P, Stewart JH, Sugarbaker PH, Barone RM, Hoefer R, Morris DL, Sardi A, Sticca RP. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010 Nov 1;102(6):565-70. doi: 10.1002/jso.21601.</citation>
    <PMID>20976729</PMID>
  </reference>
  <reference>
    <citation>Dromain C, Leboulleux S, Auperin A, Goere D, Malka D, Lumbroso J, Schumberger M, Sigal R, Elias D. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging. 2008 Jan-Feb;33(1):87-93.</citation>
    <PMID>17632751</PMID>
  </reference>
  <reference>
    <citation>Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094.</citation>
    <PMID>24553385</PMID>
  </reference>
  <reference>
    <citation>Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum in: Nature. 2017 Dec 20;:.</citation>
    <PMID>28445469</PMID>
  </reference>
  <reference>
    <citation>Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, Tacey M, Wong HL, Christie M, Kosmider S, Skinner I, Wong R, Steel M, Tran B, Desai J, Jones I, Haydon A, Hayes T, Price TJ, Strausberg RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016 Jul 6;8(346):346ra92. doi: 10.1126/scitranslmed.aaf6219.</citation>
    <PMID>27384348</PMID>
  </reference>
  <reference>
    <citation>Saluja H, Karapetis CS, Pedersen SK, Young GP, Symonds EL. The Use of Circulating Tumor DNA for Prognosis of Gastrointestinal Cancers. Front Oncol. 2018 Jul 24;8:275. doi: 10.3389/fonc.2018.00275. eCollection 2018. Review.</citation>
    <PMID>30087854</PMID>
  </reference>
  <reference>
    <citation>Ossandon MR, Agrawal L, Bernhard EJ, Conley BA, Dey SM, Divi RL, Guan P, Lively TG, McKee TC, Sorg BS, Tricoli JV. Circulating Tumor DNA Assays in Clinical Cancer Research. J Natl Cancer Inst. 2018 Sep 1;110(9):929-934. doi: 10.1093/jnci/djy105. Review.</citation>
    <PMID>29931312</PMID>
  </reference>
  <reference>
    <citation>Yang QM, Bando E, Kawamura T, Tsukiyama G, Nemoto M, Yonemura Y, Furukawa H. The diagnostic value of PET-CT for peritoneal dissemination of abdominal malignancies. Gan To Kagaku Ryoho. 2006 Nov;33(12):1817-21.</citation>
    <PMID>17212117</PMID>
  </reference>
  <reference>
    <citation>Yonemura Y, Elnemr A, Endou Y, Hirano M, Mizumoto A, Takao N, Ichinose M, Miura M, Li Y. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. 2010 Feb 15;2(2):85-97. doi: 10.4251/wjgo.v2.i2.85.</citation>
    <PMID>21160926</PMID>
  </reference>
  <reference>
    <citation>Satoh Y, Ichikawa T, Motosugi U, Kimura K, Sou H, Sano K, Araki T. Diagnosis of peritoneal dissemination: comparison of 18F-FDG PET/CT, diffusion-weighted MRI, and contrast-enhanced MDCT. AJR Am J Roentgenol. 2011 Feb;196(2):447-53. doi: 10.2214/AJR.10.4687.</citation>
    <PMID>21257899</PMID>
  </reference>
  <reference>
    <citation>Brücher BL, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, Gonzalez-Moreno S, Pelz J, Königsrainer A, Ströhlein M, Levine EA, Morris D, Bartlett D, Glehen O, Garofalo A, Nissan A. Peritoneal carcinomatosis: cytoreductive surgery and HIPEC--overview and basics. Cancer Invest. 2012 Mar;30(3):209-24. doi: 10.3109/07357907.2012.654871. Review.</citation>
    <PMID>22360361</PMID>
  </reference>
  <reference>
    <citation>Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009 Feb;16(2):327-33. doi: 10.1245/s10434-008-0234-2. Epub 2008 Dec 3.</citation>
    <PMID>19050972</PMID>
  </reference>
  <reference>
    <citation>Rausei S, Ruspi L, Mangano A, Lianos GD, Galli F, Boni L, Roukos DH, Dionigi G. Advantages of staging laparoscopy in gastric cancer: they are so obvious that they are not evident. Future Oncol. 2015;11(3):369-72. doi: 10.2217/fon.14.283.</citation>
    <PMID>25675119</PMID>
  </reference>
  <reference>
    <citation>Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989;46(5):318-22.</citation>
    <PMID>2779946</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ctDNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

